RUSSIAN ASSOCIATION OF PEDIATRIC SURGEONS. DIAGNOSTICS AND TREATMENT OF INFANTILE HEMANGIOMAS. DRAFT CONSENSUS DOCUMENT



如何引用文章

全文:

作者简介

Yu. Polyaev

编辑信件的主要联系方式.
Email: noemail@neicon.ru
俄罗斯联邦

A. Myl'nikov

Email: noemail@neicon.ru
俄罗斯联邦

I. Abushkin

Email: noemail@neicon.ru
俄罗斯联邦

A. Butorina

Email: noemail@neicon.ru
俄罗斯联邦

R. Garbuzov

Email: noemail@neicon.ru
俄罗斯联邦

A. Denis

Email: noemail@neicon.ru
俄罗斯联邦

I. Zyabkin

Email: noemail@neicon.ru
俄罗斯联邦

N. Kotlukova

Email: noemail@neicon.ru
俄罗斯联邦

D. Kupatadze

Email: noemail@neicon.ru
俄罗斯联邦

A. Narbutov

Email: noemail@neicon.ru
俄罗斯联邦

I. Nurmeev

Email: noemail@neicon.ru
俄罗斯联邦

D. Romanov

Email: noemail@neicon.ru
俄罗斯联邦

A. Petrushin

Email: noemail@neicon.ru
俄罗斯联邦

R. Hagurov

Email: noemail@neicon.ru
俄罗斯联邦

参考

  1. Haggstrom A.N., Drolet B.A., Baselga E. et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006; 118 (3): 882-7.
  2. Drolet B.A., Frommelt P.C., Chamlin S.L. et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013; 131 (1): 128-40.
  3. Hoeger P.H., Harper J.I., et al. Treatment of infantile haemangiomas: recommendations of a European expert group. The European Journal of Pediatrics. 2015; 174 (7): 855-65.
  4. Baselga Torres, Bernabéu Wittel et al. Spanish consensus on infantile haemangioma. An. Pediat.r (Barc). 2016; 85(5): 256-65.
  5. Smithson S.L., Rademaker M. et al. Consensus statement for the treatment of infantile haemangiomas with propranolol. Australasian Journal of Dermatology. 2017; 58(2): 155-9.
  6. Vleuten C., Schultze Kool L., Verhoeven B. et al. Consensusdocument voor de behandeling van infantiele hemangiomen. 2017hevas.eu›HEVAS_richtlijnen_2017_WEB.
  7. Solman L., Glover M. et al. Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines. British Journal of Dermatology. 2018; 179(3): 582-9.
  8. https://www.issva.org
  9. Tollefson M.M., Frieden I.J. et al. Early Growth of Infantile Hemangiomas: What Parents’ Photographs Tell Us. Pediatrics. 2012; 130(2): 314-20.
  10. Chang L.C., Haggstrom A.N. et al. Growth Characteristics of Infantile Hemangiomas: Implications for Management. Pediatrics. 2008; 122(2); 360-7.
  11. Mulliken J.B., Enjolras O. Congenital hemangiomas and infantile hemangioma: missing links. J Am Acad Dermatol. 2004; 50(6): 875-82.
  12. Haggstrom A.N., Lammer E.J. et al. Patterns of Infantile Hemangiomas: New Clues to Hemangioma Pathogenesis and Embryonic Facial Development. Pediatrics. 2006; 117(3): 698-703.
  13. Nabatian A.S., Milgraum S.S., Hess C.P. et al. PHACE without face? Infantile hemangiomas of the upper body region with minimal or absent facial hemangiomas and associated structural malformations. Pediatric dermatology. 2011; 28(3): 235-41.
  14. Christison-Lagay E.R., Burrows P.E., Alomari A. et al. Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry. J. Pediatr. Surg. 2007; 42(1): 62-7.
  15. Iacobas I., Phung T.L. et al. Guidance Document for Hepatic Hemangioma (Infantile and Congenital) Evaluation and Monitoring. J. Pediatr. Surg. 2018; 203: 294-300.
  16. Huang S.A., Tu H.M., Harney J.W. et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N. Engl. J Med. 2000; 343(3): 185-9.
  17. Bayart C.B., Tamburro J.E. et al. Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study. Pediatr Dermatol. 2017; 34(4): 413-21.
  18. Leaute-Labreze C., Hoeger P., Mazereeuw-Hautier J. et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N. Engl. J. Med. 2015; 372:735-46.
  19. Wedgeworth E., Glover M., Irvine A.D. et al. Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. British Journal of Dermatology. 2016; 174(3): 594-601.
  20. Chang L., Gu Y., Yu Z. et al. When to stop propranolol for infantile hemangioma. Scientific Reports. 2017; 22(7): 43292.
  21. Буторина А.В. Лечение сосудистых новообразований у детей: метод, рек. М., 2000. 42с
  22. Bartoshesky L.E. Corticosteroid treatment of cutaneous hemangiomas: how effective a report on 24 children. Clin. Pediatr. 1978; 17: 629-38.
  23. Nguyen J.F., Fay A. Pharmacologic therapy for periocular infantile hemangiomas: a review of the literature. Semin. Ophthalmol. 2009; 24(3): 178-84.
  24. George M.E., Sharma V. et al. Adverse Effects of Systemic Glucocorticosteroid Therapy in Infants With Hemangiomas. Arch. Dermatol. 2004; 140(8): 963-9.
  25. Cogen M.S. Eyelid depigmentation following corticosteroid injection for infantile ocular adnexal hemangioma. J. Pediatr. Ophthalmol. Strabismus. 1989; 26 (1): 35-8.
  26. Gawrych E. Intralesional corticosteroid therapy in infantile hemangiomas. Ann. Acad. Med. Stetin. 2009; 55(1): 15-21.
  27. Pope E. Oral Versus High-Dose Pulse Corticosteroids for Problematic Infantile Hemangiomas: A Randomized, Controlled Trial. Pediatrics. 2007; 119(6): 1239-47.
  28. Gnarra M., Solman L., Harper J.I., Syed S.B. Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. Br J Dermatol. 2015l; 173(1): 242-6.
  29. Breur J.M., de Graaf M., Breugem C.C., Pasmans S.G. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol. 2011; 28(2): 169-71.
  30. Greenberger S., Yuan S., Walsh L.A. et al. Rapamycin suppresses self-renewal and vsculogenic potential of stem cells isolated from infantile hemangioma. J. Invest. Dermatol. 2011; 131(12): 2467-76.
  31. Kaylani S., Theos A.J., Pressey J.G. Treatment of infantile hemangiomas with sirolimus in a patient with PHACE syndrome. Pediatr. Dermatol. 2013; 30(6): 194-7.
  32. Hutchins K.K., Ross R.D., Kobayashi D. et al. Treatment of Refractory Infantile Hemangiomas and Pulmonary Hypertension With Sirolimus in a Pediatric Patient. Journal of Pediatric Hematology Oncology. 2017; 39(7): 391-3.
  33. Frommelt P., Juern A., Siegel D., et al. Adverse Events in Young and Preterm Infants Receiving Topical Timolol for Infantile Hemangioma. Pediatric dermatology. 2016; 33(4): 405-14.
  34. Puttgen K., Lucky A., Adams D. et al. Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics. 2016; 138(3).
  35. Tay Y.K., Tan S.K. Treatment of infantile hemangiomas with the 595-nm pulsed dye laser using different pulse widths in an Asian population. Lasers Surg Med.2012; 44(2): 93-6.
  36. Kessels J.P., Hamers E.T., Ostertag J.U. Superficial hemangioma: pulsed dye laser versus wait- and-see. Dermatol. Surg. 2013; 39(3 Pt 1): 414-21.
  37. Civas E., Koc E., Aksoy B., Aksoy H.M. Clinical experience in the treatment of different vascular lesions using a neodymium-doped yttrium aluminum garnet laser. Dermatol Surg. 2009; 35(12): 1933-41.
  38. Hartmann F., Lockmann A. Nd:YAG and pulsed dye laser therapy in infantile haemangiomas: a retrospective analysis of 271 treated haemangiomas in 149 children. Journal of the European Academy of Dermatology and Venereology. 2017; 31(8): 1372-9.
  39. https://www.kinderformularium.nl/

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © , 2020

##common.cookie##